Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.30 |
| ▸ | CDK9 | P50750 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13922398 | 0.97 | GABRA1 (0.32) | CNR2GABRA1GABRB2 | |
| SCHEMBL8939381 | 0.96 | CNR2 (0.34) | CNR2GABRA1GABRB2CNR1 | |
| SCHEMBL13922400 | 0.96 | GABRA1 (0.32) | CNR2GABRA1GABRB2 | |
| SCHEMBL13922399 | 0.96 | GABRA1 (0.32) | CNR2GABRA1GABRB2 | |
| SCHEMBL13922396 | 0.95 | GABRA1 (0.35) | GABRA1GABRB2CCNT1CDK9 | |
| SCHEMBL13922449 | 0.94 | CNR2 (0.31) | CNR2 | |
| SCHEMBL8939380 | 0.93 | GABRA1 (0.34) | CNR2GABRA1GABRB2CNR1 | |
| SCHEMBL8939382 | 0.92 | GABRA1 (0.33) | CNR2GABRA1GABRB2CNR1 | |
| SCHEMBL8939385 | 0.92 | GABRA1 (0.33) | CNR2GABRA1GABRB2CNR1 | |
| SCHEMBL8939387 | 0.92 | GABRA1 (0.33) | CNR2GABRA1GABRB2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7510749-B2 | Difluorobenzene derivative, alkenyl, cyclohexenyl; increased voltage holding ratio; high clearing point, low minimum temperature liquid crystal phase, enhanced temperature range of nematic phase; display device useful in wide temperature range; small viscosity, large elastic constant, fast response time | CHISSO CORPORATION (JP) | 2009-03-31 | — | — | US | disclosed |
| US-20080063814-A1 | Difluorobenzene derivative, alkenyl, cyclohexenyl; increased voltage holding ratio; high clearing point, low minimum temperature liquid crystal phase, enhanced temperature range of nematic phase; display device useful in wide temperature range; small viscosity, large elastic constant, fast response time | CHISSO CORPORATION | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080063814-A1 | Difluorobenzene derivative, alkenyl, cyclohexenyl; increased voltage holding ratio; high clearing point, low minimum temperature liquid crystal phase, enhanced temperature range of nematic phase; display device useful in wide temperature range; small viscosity, large elastic constant, fast response time | POU2F2, HCN2, POU2F1 | CNR2 673/4885PTGES 4394/4885ALOX5 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.